Cargando…

The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot study

OBJECTIVE: To evaluate the efficacy and safety of pentosan polysulfate sodium (PPS, Elmiron®) for dyslipidaemia and knee osteoarthritis (OA) related symptoms. METHOD: This was a single-arm, open-label, prospective, non-randomised pilot study. People with painful knee OA and a history of primary hype...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoqian, Virk, Sonika, Fedorova, Tatyana, Oo, Win Min, Hunter, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985017/
https://www.ncbi.nlm.nih.gov/pubmed/36879559
http://dx.doi.org/10.1016/j.ocarto.2023.100343
_version_ 1784900862388207616
author Liu, Xiaoqian
Virk, Sonika
Fedorova, Tatyana
Oo, Win Min
Hunter, David J.
author_facet Liu, Xiaoqian
Virk, Sonika
Fedorova, Tatyana
Oo, Win Min
Hunter, David J.
author_sort Liu, Xiaoqian
collection PubMed
description OBJECTIVE: To evaluate the efficacy and safety of pentosan polysulfate sodium (PPS, Elmiron®) for dyslipidaemia and knee osteoarthritis (OA) related symptoms. METHOD: This was a single-arm, open-label, prospective, non-randomised pilot study. People with painful knee OA and a history of primary hypercholesterolemia were included. PPS was taken orally in a dosage of 10 ​mg/kg once every 4 days for 5 weeks for two cycles. There was 5 weeks of no medication between the cycles. The main outcomes included the change in lipidemia levels, the change in knee OA-related symptoms assessed by pain numerical rating scale (NRS) and Knee Osteoarthritis Outcome Score (KOOS), and knee MRI semi-quantitative score. The changes were analysed using paired t-tests. RESULTS: 38 participants were included, with a mean age of 62.2 years. We found a statistically significant decrease in total cholesterol (from 6.23 ​± ​0.74 to 5.95 ​± ​0.77 ​mmol/L; P ​= ​0.01) and low-density lipoprotein (from 4.03 ​± ​0.61 to 3.82 ​± ​0.61 ​mmol/L; P ​= ​0.009) from baseline to week 16. Knee pain NRS was significantly reduced at weeks 6, 16 and 26 from 6.39 ​± ​1.33 to 4.18 ​± ​1.99, 3.63 ​± ​2.28 and 4.38 ​± ​2.55, respectively (P ​< ​0.001). However, there was no significant difference in terms of the primary outcome of triglyceride levels before and after treatment. The most common AEs were positive faecal occult blood tests, followed by headache and diarrhoea. CONCLUSION: The findings suggest that PPS has promising effects on improving dyslipidaemia and symptomatic pain relief in people with knee OA.
format Online
Article
Text
id pubmed-9985017
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99850172023-03-05 The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot study Liu, Xiaoqian Virk, Sonika Fedorova, Tatyana Oo, Win Min Hunter, David J. Osteoarthr Cartil Open Clinical Trial OBJECTIVE: To evaluate the efficacy and safety of pentosan polysulfate sodium (PPS, Elmiron®) for dyslipidaemia and knee osteoarthritis (OA) related symptoms. METHOD: This was a single-arm, open-label, prospective, non-randomised pilot study. People with painful knee OA and a history of primary hypercholesterolemia were included. PPS was taken orally in a dosage of 10 ​mg/kg once every 4 days for 5 weeks for two cycles. There was 5 weeks of no medication between the cycles. The main outcomes included the change in lipidemia levels, the change in knee OA-related symptoms assessed by pain numerical rating scale (NRS) and Knee Osteoarthritis Outcome Score (KOOS), and knee MRI semi-quantitative score. The changes were analysed using paired t-tests. RESULTS: 38 participants were included, with a mean age of 62.2 years. We found a statistically significant decrease in total cholesterol (from 6.23 ​± ​0.74 to 5.95 ​± ​0.77 ​mmol/L; P ​= ​0.01) and low-density lipoprotein (from 4.03 ​± ​0.61 to 3.82 ​± ​0.61 ​mmol/L; P ​= ​0.009) from baseline to week 16. Knee pain NRS was significantly reduced at weeks 6, 16 and 26 from 6.39 ​± ​1.33 to 4.18 ​± ​1.99, 3.63 ​± ​2.28 and 4.38 ​± ​2.55, respectively (P ​< ​0.001). However, there was no significant difference in terms of the primary outcome of triglyceride levels before and after treatment. The most common AEs were positive faecal occult blood tests, followed by headache and diarrhoea. CONCLUSION: The findings suggest that PPS has promising effects on improving dyslipidaemia and symptomatic pain relief in people with knee OA. Elsevier 2023-02-07 /pmc/articles/PMC9985017/ /pubmed/36879559 http://dx.doi.org/10.1016/j.ocarto.2023.100343 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Trial
Liu, Xiaoqian
Virk, Sonika
Fedorova, Tatyana
Oo, Win Min
Hunter, David J.
The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot study
title The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot study
title_full The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot study
title_fullStr The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot study
title_full_unstemmed The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot study
title_short The effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: A pilot study
title_sort effect of pentosan polysulfate sodium for improving dyslipidaemia and knee pain in people with knee osteoarthritis: a pilot study
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985017/
https://www.ncbi.nlm.nih.gov/pubmed/36879559
http://dx.doi.org/10.1016/j.ocarto.2023.100343
work_keys_str_mv AT liuxiaoqian theeffectofpentosanpolysulfatesodiumforimprovingdyslipidaemiaandkneepaininpeoplewithkneeosteoarthritisapilotstudy
AT virksonika theeffectofpentosanpolysulfatesodiumforimprovingdyslipidaemiaandkneepaininpeoplewithkneeosteoarthritisapilotstudy
AT fedorovatatyana theeffectofpentosanpolysulfatesodiumforimprovingdyslipidaemiaandkneepaininpeoplewithkneeosteoarthritisapilotstudy
AT oowinmin theeffectofpentosanpolysulfatesodiumforimprovingdyslipidaemiaandkneepaininpeoplewithkneeosteoarthritisapilotstudy
AT hunterdavidj theeffectofpentosanpolysulfatesodiumforimprovingdyslipidaemiaandkneepaininpeoplewithkneeosteoarthritisapilotstudy
AT liuxiaoqian effectofpentosanpolysulfatesodiumforimprovingdyslipidaemiaandkneepaininpeoplewithkneeosteoarthritisapilotstudy
AT virksonika effectofpentosanpolysulfatesodiumforimprovingdyslipidaemiaandkneepaininpeoplewithkneeosteoarthritisapilotstudy
AT fedorovatatyana effectofpentosanpolysulfatesodiumforimprovingdyslipidaemiaandkneepaininpeoplewithkneeosteoarthritisapilotstudy
AT oowinmin effectofpentosanpolysulfatesodiumforimprovingdyslipidaemiaandkneepaininpeoplewithkneeosteoarthritisapilotstudy
AT hunterdavidj effectofpentosanpolysulfatesodiumforimprovingdyslipidaemiaandkneepaininpeoplewithkneeosteoarthritisapilotstudy